INTRODUCTION
Mast cells (MCs) are normal residents of mucosal tissues, but their numbers and anatomical location can change markedly during immune responses, infections, and other disorders affecting such sites, in humans, mice, and other species. [1] [2] [3] [4] [5] MCs stimulated via the high-affinity receptor for IgE (FceRI) or by any of multiple other mechanisms can release a diverse spectrum of biologically active mediators, and such products, individually or in aggregate, can have many different effects on immune or structural cells present in mucosal tissues. 4, [6] [7] [8] As a result, there is no lack of ideas about the potential effector or immunoregulatory functions MCs might have during mucosal immune responses. 3, 4, 8 However, it can be quite challenging to prove that MCs can perform such proposed functions in vivo, and even more difficult, in light of the potential redundancy of effector and immunoregulatory mechanisms, to assess the biological importance of such MC functions in particular settings. In this review, we will outline some basic principles of MC biology and then consider evidence that implicates MCs in physiological, immunological, and pathological processes affecting mucosal sites. We will particularly focus on findings derived from studies in mice, a species in which biological responses can be analyzed in animals that lack MCs or specific MC-associated products.
MC DEVELOPMENT, PHENOTYPE, TISSUE DISTRIBUTION, AND PLASTICITY
MCs are tissue-resident cells that arise from hematopoietic progenitors. 9 Unlike other immune cells, MCs normally do not mature before leaving the bone marrow but circulate through the vascular system as immature progenitors that complete their development peripherally within the connective or mucosal tissues, or in serosal cavities, in a process potentially regulated by multiple local factors. [3] [4] [5] 10, 11 The KIT ligand stem cell factor (SCF) has a critical role in MC biology by regulating the development, migration, growth, survival, and local activation of MCs. [12] [13] [14] Various other factors also can modulate MC growth and survival, including interleukin (IL)-3, 15 IL-4, [16] [17] [18] [19] IL-9, 20,21 IL-10, [22] [23] [24] IL-33, [25] [26] [27] CXCL12, 28, 29 transforming growth factor-b, 30 and nerve growth factor. 31 MCs reside in almost all vascularized tissues and can be especially numerous in those exposed to the external environment, such as the skin and mucosal sites. 3 MCs are, therefore, well positioned to respond to various allergens, pathogens, and other agents that can be ingested, inhaled, or encountered after disruption of the epithelial barrier. 8 Moreover, many phenotypic and functional characteristics of MCs, such as their proliferation, survival, and ability to store and/or secrete various products, can be modulated or ''tuned'' by many genetic and environmental factors, including changes in the cytokine milieu associated with inflammatory or immune responses. 8 Despite their potential phenotypic ''plasticity'', MCs are often subclassified based on certain of their ''baseline'' phenotypic characteristics and their anatomic locations ( Table 1) . In mice, two types of MCs have been described: ''connective tissue-type'' MCs (CTMCs) and mucosal MCs (MMCs). 4, 5, 8 CTMCs are often located around venules and near nerves and reside in serosal cavities, whereas MMCs T-cell dependence T cells required for baseline populations and for expansion (e.g., in response to parasites) 32 Do not require T cells for baseline populations or for expansion
Reduced numbers in subjects with congenital or acquired deficiencies in T cells 41 Normal numbers in subjects with congenital or acquired deficiencies in T cells 41 Anatomical distribution (at baseline) Glandular stomach mucosa (many at baseline), small intestinal and colonic mucosae (very few at baseline), and respiratory mucosa [344] [345] [346] Skin, serosal cavities, tongue, submucosa, and muscularis of the stomach, trachea, and around the large airways 155, 346 Preponderance of MCs in nasal and bronchial mucosae, lung alveoli, conjunctiva, gastric, small intestinal, and colonic mucosae 40, 42 Preponderance of MCs in skin, gastric, small intestinal and colonic submucosa and muscularis, bronchial submucosa, smooth muscle of major bronchi, conjunctiva, breast parenchyma, and axillary lymph nodes 40, 42 Proteoglycan content Little or no heparin; 347, 348 chondroitin sulfate di-B, A, E 349, 350 Heparin; 347, 348 chondroitin sulfate E 349, 350 Heparin; 351 chondroitin sulfate A, E 349, 350 Heparin; 351 chondroitin sulfate A, E 349, 350 Protease content Express predominantly the chymases MCPT1 and 2 5, 118, 175, 352 Express predominantly the chymase MCPT4, the elastase MCPT5, the tryptases MCPT6 and 7 and Carboxypeptidase A3 5, 118, 175, 352 Tryptase (a, b(I-III), and g) 353-355,b ; little or no chymase, carboxypeptidase A3 and cathepsin G 38, 356, 357 Tryptase (a, b(I-III), and g) 353 Many aspects of the phenotype of MC populations can vary based on whether the MCs are present at sites of inflammatory or immune responses, their exposure to various growth factors and other cytokines, and/or the history of their activation for secretion. 175 Accordingly, the features listed in the table are primarily those of MC populations at ''baseline'' in the tissues mentioned. These MC subpopulations can vary in features not covered in the table, such as in their sensitivity to pathogen-associated molecular patterns and in the spectrum of cytokines, chemokines, and growth factors that they can secrete or respond to. However, much of the evidence for such differences is based on in vitro rather than in vivo studies, and these features also may be subject to variation in vivo depending on the biological setting. CTMC, connective tissue-type mast cell; FcgR, receptor for IgG; FceRI, high-affinity receptor for IgE; MCPT, mast cell protease; MMC, mucosal mast cell; MC T , tryptaseexpressing mast cell, MCTC, tryptase and chymase-expressing mast cell. a Not all features listed have been reported for MCs in each anatomic site. b In humans, a tryptases have no or minimal catalytic activity and are absent in many people, whereas b tryptases are active (bI and bII) or are predicted to be active (bIII); tryptase deficiency alleles are common, and different populations of humans differ in whether they inherit two vs. four active alleles. 378 The more recently described g-tryptases are expressed at the mRNA level in multiple MC populations but less is known about the distribution of the protein in various MC populations.
occupy the mucosae of the gut and respiratory mucosa. 5 MMCs are found at relatively low numbers in most mucosal tissues (in mice, they are normally present in higher numbers in the glandular stomach mucosa than in the intestines), but the expansion of MMC populations can be induced in a T-cell-dependent manner. 5, 32 CTMCs and MMCs often are distinguished based on their protease content ( Table 1) . Mouse intestinal MMCs elicited during parasite infection express the chymase mouse MC protease-1 (MCPT1) but not the elastase MCPT5, whereas CTMCs do not express MCPT1 but express MCPT5, the chymase MCPT4, and the tryptases MCPT6 and MCPT7 5, 33, 34 (notably, C57BL/6 mice do not express MCPT7 because of a point mutation in the exon/intron 2 splice of the Mcpt7 gene 35 ). However, the plasticity of MC phenotype can make such a classification challenging, as features of the cells, including their protease content, may vary during the course of immune responses. 5, 8, 33, 36, 37 In humans, MCs can be subcategorized into MC T , which express high levels of the MC-specific protease tryptase but little or no chymase (these, therefore, are thought to resemble rodent MMCs), and MC TC , which express both tryptase and chymase (and in that respect resemble rodent CTMCs) 38, 39 ( Table 1) . MC C (which express chymase but little or no tryptase) also have been described, but they appear to be infrequent. 40 Clinical evidence suggests that human MC T (like mouse MMCs) may be dependent on T cells, at least in part, to maintain normal numbers in mucosal sites. 41 The majority of human lung MCs ordinarily are MC T (B90%) and these cells are found in the bronchial/bronchiolar lamina propria and alveoli. 42 MC TC typically are located beneath the epithelium in the lamina propria and submucosa, in close proximity to submucosal glands, and some MC TC are found within and around the airway smooth muscle layers of major bronchi. 43 The lamina propria of the human intestinal mucosa normally contains B1.5-3% MCs. 44, 45 In the human small intestine, MC T represent B98% of all MCs in the mucosa and B13% of MCs in the submucosa are MC T . 42 In naïve mice, relatively low numbers of MCs are found in the lung and these cells are located around the larger airways and blood vessels. As noted above, in naïve mice, few MCs are found in the mucosa of the gastrointestinal tract except for the glandular stomach and small numbers can be found in the submucosa and muscularis propria.
However, MC numbers at mucosal sites can increase in both humans and mice in pathological settings such as inflammatory bowel disease, 46, 47 food allergy, 48, 49 parasite infections, 50, 51 asthma, [52] [53] [54] [55] [56] or various types of lung fibrosis. [57] [58] [59] [60] Such increases in MC numbers could reflect, at least in part, the division of mature MCs at mucosal sites. Although MCs are often considered as terminally differentiated cells that cannot divide, we and others have provided evidence that at least certain ''mature'' MCs, i.e., those that can be identified morphologically based on their abundant cytoplasmic granules retain some proliferative ability. [61] [62] [63] [64] Increased MC numbers in such settings also may reflect the maturation of increased numbers of MC progenitors, whose numbers in tissues may increase due to their increased recruitment and/or survival in such tissues, and/or via the local proliferation of such progenitors. 5 66 observed a fourfold expansion of MC progenitors in the intestine following sensitization and challenge of mice with the antigen ovalbumin (OVA). Antigen-dependent expansion of MC progenitors also was observed in mouse lung following sensitization and challenge with aerosolized OVA, and IL-9 and CD4 þ T cells were found to contribute to such expansion. 67 Finally, it has been reported that certain MC progenitors can proliferate in vitro; 66 however, whether they can also proliferate within mucosal tissues remains to be proven.
MC ACTIVATION
MCs ordinarily express on their surface large numbers of the high-affinity IgE receptor, FceRI. During IgE-dependent immune responses, the antigen-dependent cross-linking of antigen-specific IgE bound to FceRI induces the aggregation of FceRI, promoting the activation of downstream signaling events that lead to the secretion of biologically active products implicated in allergic reactions. 6, 68, 69 The IgE-dependent stimulation of MCs has been extensively reviewed. 6, [69] [70] [71] [72] It was recently reported that perivascular MCs can ''sample'' circulating IgE directly in the blood by extending cell processes across the vessel wall. 73 Moreover, MC FceRI were shown to be able to distinguish between high-or low-affinity stimuli, permitting the MCs to respond differentially to such signals by releasing distinct spectra of secretory products in vitro and by orchestrating distinct in vivo outcomes. 74 Our group recently reported a beneficial role for IgE, FceRIa, and FceRIg in defense against honeybee venom-induced mortality in mice. 75 Together with the evidence that expression of the FceRIa chain is important for the full expression of acquired resistance to the hypothermia-inducing effect of honeybee venom-derived phospholipase A 2 , 76 these findings support the hypothesis that IgE, which contributes to allergic disorders, also has an important function in protection of the host against noxious substances.
77,78
MCs can respond to many stimuli beside IgE. MCs can respond to various pathogens through the activation of TLRs, including TLR-2 and TLR-4 79, 80 and, via G-protein-coupled receptors, to certain peptides found in venoms, [81] [82] [83] or can be activated by various complement peptides 84, 85 and plateletactivation factor. 86 There is evidence that MCs also can be directly or indirectly activated by some plant products, including aqueous pollen extracts from birch, 87 and by products of the coagulation system, including Factor Xa 88 and thrombin receptor-activating peptide. 89 MCs also can respond to certain chemokines and cytokines (including IL-33 [25] [26] [27] 90, 91 and TSLP 92 ), or be activated through the aryl hydrocarbon receptor, 93, 94 the CD40 ligand, 95 or the OX40 ligand [96] [97] [98] 
MOUSE MODELS TO STUDY MC FUNCTIONS IN VIVO
Pharmacological agents thought to target MC activation or MC proteases have been used in vivo to assess the functions of MCs. However, none of the drugs or antibodies described to date is fully specific for MCs or for particular MC proteases. 70, 152, 153 Therefore, we favor using genetic approaches to gain insights into MCs functions in vivo. c-kit-independent MC-deficient mice and mice deficient for MC-associated products
More recently, several groups have generated new strains of mice permitting the constitutive or inducible deletion of MCs independently of mutations affecting c-kit structure or expression. 60, [167] [168] [169] [170] [171] [172] Most of these groups used a strategy consisting of generating transgenic mice expressing the Cre recombinase under the control of promoters for MC proteases, such as those for Cpa3 or MC protease 5 (Mcpt5). 167, 168, 172 Such mice then were crossed with mice in which the genes of interest have been ''floxed'' to delete the expression of these gene products in the MCs. 168, 173 Our group mated Cpa3-Cre mice with mice expressing the floxed survival factor Mcl-1: the resulting Cpa3-Cre; Mcl-1 fl/fl mice were severely deficient in MCs but had also markedly reduced basophil levels. 167 Feyerabend et al. 172 reported a severe MC deficiency (and a more modest deficiency in basophils) in another line of Cpa3-Cre mice due to Cre-mediated cytotoxicity. Mcpt5-Cre mice, which express Cre in connective tissue-type MCs but not MMCs, 168, 169 were mated with transgenic mice expressing Cre inducible diphtheria toxin A (DTA) or diphtheria toxin receptor (iDTR) genes to achieve constitutive (in Mcpt5-Cre; DTA þ mice) or inducible (after DT injection in Mcpt5-Cre; iDTR þ mice) ablation of CTMCs. 168 All of these mice and some additional new types of MC-deficient mice have been recently reviewed in detail. 152, 174, 175 Several strains of mice that are deficient for one or multiple MC-associated proteases, or are unable to synthesize histamine (due to a deficiency in histidine decarboxylase) or heparin (due to a deficiency in N-deacetylase/N-sulfotransferase-2), also have been developed. Although each of these strains of mice can provide important information concerning the roles of particular products released by MCs, some of them have a complex phenotype and there are a number of considerations that should be kept in mind when interpreting findings obtained with these animals, as reviewed in Reber et al., 152 Galli et al. 175 , and Wernersson and Pejler.
176

ROLE OF MAST CELLS IN THE REGULATION OF INTESTINAL EPITHELIAL PERMEABILITY
The intestinal epithelium forms a selectively permeable barrier against the external environment. 177 Disruption or dysregulation of this barrier is associated with many intestinal disorders, including bacterial, viral and parasitic infections, inflammatory bowel disease, and food allergies. 177 179 A role for MCs in this setting also was suggested by tests of pharmacological agents, which antagonize the factions of certain MC-derived mediators. 179 Infection with the parasite Trichinella spiralis (T. spiralis) increases paracellular permeability of the jejunum and decreases the expression of occludin in the tight junctions of enterocytes. 181 Treatment of WT mice with a c-kit blocking antibody abrogated MC hyperplasia during T. spiralis infection and blocked parasite-induced increases in intestinal permeability. 181 Mice deficient in the chymase MCPT1 also exhibited diminished intestinal permeability during T. spiralis infection, even though numbers of intestinal MMCs were higher during infection in Mcpt1 À / À mice than in WT mice.
181
Injection of the neuropeptide substance P induces intestinal ion secretion with increase in Isc responses. In intestinal preparations from MC-deficient Kit W/W-v mice, substance P-induced Isc responses were diminished to B50% of those observed in WT mice and were normalized by the adoptive transfer of WT BM cells, suggesting that MCs can contribute to substance P-induced changes in intestinal ion secretion. 184 By contrast, our group demonstrated that MCs can limit the toxicity associated with high concentrations of another neuropeptide, VIP (vasoactive intestinal polypeptide). 82 In that setting, our evidence indicated that VIP induced MC degranulation, releasing the chymase MCPT4, which then degraded VIP. 82 
ROLES OF MAST CELLS IN ALLERGIC RESPONSES AT MUCOSAL SITES Asthma
Asthma is a multifaceted disorder characterized by reversible airway narrowing (in many patients in response to particular allergens), immunologically nonspecific airway hyperresponsiveness (AHR), chronic inflammation of the airways, and airway remodeling, including fibrosis, goblet cell hyperplasia/ metaplasia, increased mucus production, smooth muscle thickening, and increased vascularity. [185] [186] [187] Early manifestations of the disorder can appear in childhood, and both genetic 188 and environmental factors 189 contribute to the development and progression of asthma. Rather than being a single ''disease'', the disorder called asthma is likely comprised of distinct subphenotypes with different clinical characteristics and underlying mechanisms. [190] [191] [192] Analysis of lung epithelial brush biopsies, bronchoalveolar lavage fluids, lung biopsies, and autopsies have shown increased numbers of MCs in the airways of some asthmatic subjects 54, [193] [194] [195] but not others. 194, 196, 197 One feature more often seen in asthmatic subjects than in those without the disease is the presence of MCs within the bronchial epithelium. [198] [199] [200] In subjects with asthma, B-cell class switching to IgE occurs in the lymph nodes, 201 as well as locally in the respiratory mucosa. 202 IgE binds to FceRI, highly expressed on MCs and basophils, but also, in certain settings by eosinophils and neutrophils; evidence has been reported that FceRI also can be expressed by airway epithelial and smooth muscle cells and by certain nerves (reviewed in Galli and Tsai 69 ). IgE not only permits allergen-dependent MC activation, but also enhances the stability of FceRI on the MC surface, thus increasing the levels of receptor expression of FceRI, contributing to the maintenance of a positive amplification loop (reviewed in Kalesnikoff and Galli 6 ). Several mouse models of allergic airway inflammation have been developed to recapitulate many aspects of asthma. Studies using the MC knock-in model in c-kit mutant mice sensitized with an antigen in the absence of artificial adjuvant, 55, 56, [203] [204] [205] [206] or employing relatively low doses of antigen for sensitization or challenge, 207, 208 have provided evidence that MCs and MCderived TNF can amplify multiple features of allergic airway inflammation, including airway responsiveness, inflammation, and tissue remodeling. 55, 56, [203] [204] [205] 207, 208 However, contributions of MCs to various features of allergic asthma are not observed (perhaps because they are redundant) in some models of allergic airway inflammation employing strong artificial adjuvants (such as alum) and relatively high doses of antigen for sensitization and challenge. 203, [209] [210] [211] [212] Genetic background also can influence the contribution of MCs to allergic airway inflammation. Becker et al. 213 confirmed that Kit W-sh/W-sh mice on the C57BL/6 background have reduced airway inflammation and AHR in an adjuvant-free model of asthma, but found no significant differences between BALB/c-Kit W-sh/W-sh and BALB/c WT mice in their model. These findings clearly indicate that roles of MCs in this asthma model that are important in one strain background (the ''Th1-biased'' C57BL/6 background) may not be important (or may be redundant) in the more ''Th2-biased'' BALB/c background. These findings are of substantial interest, given the strong evidence that genetic factors have an important role in human asthma.
In a mouse model of chronic allergic airway inflammation, studies in MC knock-in mice indicated that MC expression of the IFN-gR contributes to the development of many features of the model that also require MCs and FceRIg for optimal expression, including AHR, neutrophil, and eosinophil infiltration in the lung, lung collagen deposition, and increased expression of lung IL-6, IL-13, IL-33, multiple chemokines, arginase-1, and the acute-phase protein serum amyloid A3. However, the expression of IFN-gR also contributes to some features of the model, which require MCs for optimal expression but that occur relatively independently of FceRIg, such as elevations of levels of integrin a7 and the macrophage receptor with collagenous structure in the affected lungs. 56 In a passive model of OVA-induced allergic airway inflammation, transfer of OVA 323-339 -peptide-specific, IFN-g-producing Th1 cells to naïve mice primed them to develop airway neutrophilia and AHR that was most prominent in mice challenged with LPS as well as antigen. 214 It also has been reported that co-stimulation of mouse pulmonary macrophages with LPS and IFN-g induces the production of IL-27, 215 that in turn can enhance production of IL-1 and TNF by MCs. 216 Such studies provide support for the hypothesis that bacterial infections can sustain or enhance inflammation driven by Th1 responses in asthma.
Some patients with severe asthma exhibit enhanced sputum neutrophilia (but not eosinophilia) and enhanced serum and sputum levels of IL-17. 217 In diseases with a prominent Th17 signature such as atopic dermatitis, 218 chronic exposure to antigens, such as via epicutaneous sensitization, 219 can enhance airway inflammation and ''local'' Th17 inflammation in the lung. 220 Evidence from our mouse models 55, 56 and those of others 221 show that chronic airway exposure to OVA can increase bronchoalveolar lavage neutrophils and lung levels of IL-17 (in addition to Th2 cytokines), and that the presence of MCs is essential for the development of such features. Some mouse or human MCs can produce IL-17 on non-IgEdependent stimulation (e.g., with 6-formylindolo(3,2-b)carbazole (FICZ)) or when exposed FICZ in combination with IgE/ antigen and, based on immunohistochemical findings, MCs appear to represent a major in vivo source of IL-17 in the chronically inflamed bronchial lamina propria of patients with chronic obstructive pulmonary disease, 94 and in other settings. 145, 222, 223 IL-33 is also thought to contribute to the pathology of asthma. 100, [224] [225] [226] [227] [228] The IL-33 receptor, ST2, is expressed by MCs and basophils, 229 but not by airway smooth muscle cells or lung fibroblasts. 230 In mice, IL-33-induced enhanced airway inflammation is partly dependent on IL-33-dependent MC production of IL-13.
231 IL-33 is considered an alarmin or a proinflammatory cytokine, 232 but its biology might be more complex as it has been reported that chronic exposure of human and mouse MCs to IL-33 in vitro can induce a hyporesponsive MC phenotype, raising the intriguing possibility that IL-33 might actually have certain protective roles in chronic airway inflammation. 233 In summary, evidence from studies of human asthma and mouse models of the disorder support the general conclusion that MCs can not only have critical roles in amplifying acute immunological responses to antigen and in helping to orchestrate the later development of multiple features of the disorder, but also suggest that the roles of MCs in particular subphenotypes of asthma may vary, in part, due to differences in the cytokines present in those settings (Figure 1) . Moreover, recent data raise the interesting possibility that some individual MC mediators may have effects that can restrain the development of certain features of the pathology. For example, Waernet al. 234, 235 reported that mice deficient for the chymase MCPT4 exhibit increased pathology (i.e., airway inflammation, AHR, and smooth muscle thickening) in two different models of allergic lung inflammation, and that such protective effects might reflect, at least in part, degradation of IL-33 by the chymase.
Food allergy and anaphylaxis
Food allergies are caused by adverse acquired immune responses to food components, primarily proteins. 236 Their prevalence has recently increased and food allergies now affect B6% of children and 3-4% of adults in developed countries. 236 The manifestations of food allergy can range from mild to severe, with the most severe form being anaphylaxis, an acute and potentially life-threatening multisystem reaction to allergen exposure. In the United States, the majority of cases of foodinduced fatal or near-fatal anaphylaxis are caused by peanuts or tree nuts. 237, 238 Studies in mice indicate that MCs are critical effector cells of both food-induced intestinal inflammation and anaphylaxis ( Figure 2) .
Multiple mouse models of anaphylaxis have been developed to investigate the contribution of MCs and other effector cells. Two main pathways of active anaphylaxis have been described in mice: a ''classical'' pathway consisting of antigens, IgE, FceRI, MCs, and histamine, and an ''alternative'' pathway involving IgG-antigen immune complexes, FcgRIII, platelet-activating factor (PAF), and, depending on the exact model used, macrophages, basophils, and/or neutrophils. [239] [240] [241] [242] [243] [244] [245] Several studies using Kit W/W-v and/or Kit W-sh/W-sh MC-deficient mice have provided evidence that MCs can contribute significantly to peanut-induced active anaphylaxis. 242, 244, 245 We recently confirmed these findings using c-kit-independent MC-deficient mice, by showing that selective ablation of CTMCs (induced by repeated injections of diphtheria toxin in Mcpt5-Cre; iDTR mice 168 ) significantly diminished the hypothermia induced by peanut challenge in mice sensitized orally with peanut together with the mucosal adjuvant cholera toxin. 243 However, antigen challenge induced significant hypothermia (albeit less than that in the corresponding WT mice) in Cpa3-Cre þ ; Mcl-1 fl/fl mice, which have a marked MC deficiency and a substantial reduction in basophils. 243 Antigen-induced elevations in serum histamine were abolished in MC-and basophildeficient Cpa3-Cre þ ; Mcl-1 fl/fl mice, whereas small but significant increases in PAF levels were still detected in spleen specimens from these mice. 243 Together these findings implicate the involvement of both the classical and alternative pathways of anaphylaxis in this mouse model of peanutinduced active anaphylaxis.
The reaction to peanut in some mouse models might be even more complex, as Khodoun et al. 246 found that peanut, but not milk or egg proteins, can induce shock reactions through an innate immune mechanism in mice. The authors found that this response was almost absent in mice lacking the complement factor C3 or the receptor C3aR, but developed fully in antibody-deficient Rag1 mice (which lack mature T and B cells) and mMT mice (in which the development of conventional B cells is arrested at the pro-B-cell stage). 246 However, some reports indicate that mMT mice have B1 B cells and can produce IgE and IgG. [247] [248] [249] Macrophages, basophils, and PAF contributed to this shock reaction to a greater extent than did MCs and histamine. 246 Therefore, depending on the model used, innate components might also participate importantly in peanut-induced anaphylaxis, which perhaps accounts for the fact that peanut allergy is more likely than most other forms of food allergy to cause lethal anaphylaxis. However, it is important to recognize that Khodoun et al. 246 increased the sensitivity of the mice to develop shock reactions in these experiments by pretreating the animals intravenously with a long-acting form of IL-4 (consisting on IL-4/anti-IL-4 mAb complexes, which slowly dissociate in vivo to release free IL-4) and with the b-adrenergic antagonist propranolol.
Although IgE-dependent activation of MCs is widely thought to contribute importantly to anaphylaxis in humans, subjects with food allergy-associated anaphylaxis, unlike those with insect venom-induced anaphylaxis, typically exhibit little or no elevations in blood levels of the MC-associated protease, tryptase. 250 By contrast, levels of PAF in the serum have been directly correlated with the severity of organ system involvement in patients with acute allergic reactions triggered by foods, medications, or insect stings. 251, 252 Moreover, the serum activity of PAF acetylhydrolase (an enzyme that converts PAF to the biologically inactive lyso-PAF) was significantly Individuals not yet sensitized to environmental allergens do not have specific IgE to such allergens, and few MCs are present within the epithelium (left panel). During allergic sensitization, environmental antigens (Ag) are captured by APCs in the airway lumen or in the epithelium of the airway mucosa, and Ag-activated APCs mature and migrate to regional lymph nodes, where priming of T cells occurs (not shown). The presence of IL-4 or IL-13, which may be derived from a variety of potential cellular sources, induces T cells to become T H 2 cells (right panel). In some cases, allergens also can reach APCs in the submucosa through damaged epithelium. Cytokines induced by epithelial damage (such as IL-33 and TSLP) can activate ILC2 cells, which secrete type 2 cytokines, such as IL-4 and IL-13. The Th2 environment promotes heavy-chain class switching from IgM or IgG to IgE for Ag-specific IgE production in B cells. IgE binds to FceRI on MCs (and basophils) and sensitizes these cells to respond to subsequent Ag exposures. Ag-induced aggregation of IgE-bound FceRI causes the prompt release of pre-stored MC mediators, including histamine and TNF, which can promote bronchoconstriction and, more slowly, fibroblast proliferation. FceRI activation also induces the production and the release of de novo-synthesized compounds, such as leukotrienes, prostaglandins, and proinflammatory cytokines (e.g., IL-5, IL-6, IL-8, IL-13, and TNF) and chemokines (not shown), which contribute to the development of local inflammation. Both soluble factors, such as IFN-g, TSLP, IL-33, S1P, LPS (through PRRs) and cells present at the site, such as T H cells and various T reg cells (not shown), which can interact with OX40L on MCs, modulating IgE-dependent MC activation, or B cells, which can interact with CD40L on MCs, which may enhance B-cell IgE production. At least one MC-secreted product, MCPT4 (not shown), can negatively regulate the inflammatory environment, in part through the degradation of IL-33. Repetitive exposure to specific Ag favors persistent inflammation (with large numbers of eosinophils, and with MCs appearing within the epithelium), goblet cell hyperplasia and increased mucus secretion, smooth muscle cell proliferation, increased vascular permeability (and increased numbers of blood vessels) and airway edema, thickening, and remodeling. In some asthma subtypes, genetic or environmental factors, including pathogen-derived products, tissue damage, airway pollutants, and oxidative stress, may confer strong T H 1 and/or T H 17 signatures associated with large numbers of neutrophils at the site of inflammation. Studies in MC knock-in mice have indicated that some actions of MCs, such as increasing the number of epithelial goblet cells, can occur in a model of chronic allergic inflammation by MC-dependent mechanisms that do not require MC signaling through the FceRIg chain, whereas MCs must express both the FceRIg chain and the IFN-g receptor 1 (IFN-gR1) to mediate substantial increases in lung eosinophils and neutrophils. Note: downregulatory mechanisms that can be engaged in this setting, such as co-engagement by multivalent Ag of both FceRI and FcgRIIb, or effects of regulatory T-cell populations, are not shown. AhR, Aryl hydrocarbon receptor; APC, antigenpresenting cell; Baso, basophils; Eos, eosinophils; FceRI, high-affinity receptor for IgE; IL, interleukin; ILC2, innate lymphoid cells type 2; LPS, lipopolysaccharide; MC, mast cell; Neu, neutrophils; PRR, pattern-recognition receptor; S1P, sphingosine-1-phosphate; T H , T helper; TNF, tumor necrosis factor; TSLP, thymic stromal lymphopoietin. lower in peanut-allergic patients with fatal peanut anaphylaxis than in those with mild allergic reactions to peanuts or in the control groups. 251 Although they do not constitute proof, these results are consistent with the possibility that activation of both the ''classical'' pathway and the ''alternative'' pathway might be involved in at least some examples of anaphylaxis in humans. The existence of IgG-mediated anaphylaxis in humans is perhaps best supported by the occurrence of anaphylaxis in patients infused with monoclonal antibodies, such as the chimeric mouse/human anti-TNF mAb infliximab. 239, 253 One study showed that 11 out of 165 patients with Crohn's disease treated with infliximab developed signs of anaphylaxis. All these patients had IgG antibodies to the mouse immunoglobulin determinants on infliximab. Although none of the patients had detectably increased serum levels of total IgE, the authors did not report whether they attempt to measure levels of infliximab-specific IgE. However, none of these patients had increased tryptase levels in blood 20 min after the onset of the reaction. 239, 253 Anaphylaxis represents the extreme end of a spectrum of responses to food allergens in allergic patients. In most patients, reactions are manifested mainly by local signs and symptoms, and the skin is affected in B80% of subjects. 254 Up to 50% of patients also develop gastrointestinal symptoms (abdominal pain, vomiting, and diarrhea) and a significant portion of patients also experience respiratory symptoms (cough, chest tightness, and wheezing). 255, 256 Multiple lines of evidence suggest that IgE-dependent MC activation can have an important role in these local manifestations of food allergy. Cafarelli et al. 256, 257 found elevated numbers of IgE-positive cells (plasma cells and 2.7% MCs) in duodenal biopsies from children with food allergies, whereas MCs were virtually absent in the control biopsies. Moreover, when stimulated ex vivo with anti-IgE, intestinal MCs obtained from enzymatically dispersed , and some of these MMCs are found in the intestinal epithelium. IgE binds to FceRI on MCs (and basophils) and sensitizes these cells to respond to subsequent Ag exposures. Ag-induced aggregation of IgE-bound FceRI causes the prompt release of prestored MC mediators, including histamine that can promote vasodilatation and increased vascular permeability. FceRI activation also induces the production and release of de novo-synthesized compounds, such as leukotrienes, prostaglandins, and proinflammatory cytokines (such as IL-13) and chemokines (not shown). Such MC-derived products contribute to intestinal inflammation (including the recruitment and activation of neutrophils, basophils, and eosinophils and other leukocytes), increased intestinal permeability and motility, and, in the case of parasite infections, worm expulsion. During food allergy, the activation of MCs also can promote diarrhea and, in some unfortunate individuals, anaphylaxis (not shown). IgG-Ag immune complexes can potentially modulate MC activation through Fcg receptors (MCs express the activating receptor FcgRIII and the inhibitory receptor FcgRIIb). Macrophages, basophils, and neutrophils are also activated by IgG-Ag immune complexes and release PAF, which is thought to contribute to diarrhea and anaphylaxis in food allergy. Note: downregulatory mechanisms that can be engaged in these settings, such as co-engagement by multivalent Ag of both FceRI and FcgRIIb, or effects of regulatory T-cell populations, are not shown. APC, antigen-presenting cell; Baso, basophils; Eos, eosinophils; FceRI, high-affinity receptor for IgE; FcgRs: receptors for IgGs; IL, interleukin; ILC2, innate lymphoid cells type 2; Neu, neutrophils; PAF, platelet-activating factor; PRR, pattern-recognition receptor; T H 2, T helper 2. duodenal biopsies from food allergic patients released more histamine in comparison with cells from nonallergic individuals. 256, 258 Brandt et al. 48 developed a mouse model of allergen-induced gastrointestinal inflammation consisting of sensitization with OVA together with alum and repeated oral challenges with OVA. In this model, sensitized and challenged BALB/c mice (but not C57BL/6 mice) developed large increases in numbers of MMCs in the jejunum, ileum, and colon and increased levels of MCPT1 in the plasma. These mice also exhibited a strong Th2 response in the intestine, with signs of allergy such as diarrhea and increased intestinal permeability, but without hypothermia. 48 However, systemic (intravenous) OVA challenge of OVA/alum-sensitized mice induced hypothermia that was significantly more severe in animals which had been previously challenged with OVA intragastrically compared with those mock challenged with saline. Notably, lethal anaphylactic shock occurred only in mice that previously had developed gastrointestinal allergy, suggesting that gastrointestinal allergic inflammation can prime mice for more severe anaphylaxis following systemic antigen challenge. 48 The authors showed that treatment with an anti-KIT antibody (ACK2) abrogated the diarrhea, diminished intestinal permeability, and eliminated MMCs in the jejunum. 48 These features were also diminished in mice treated with an anti-IgE antibody and in mice deficient for the high-affinity IgE receptor FceRI (but not in mice treated with a blocking antibody against the IgG receptors FcgRII/III). Finally, they demonstrated that treatment with a combination of pharmacological inhibitors of PAF and serotonin blocked diarrhea, whereas the blockade of histamine had no effect on diarrhea. 48 Wang et al. 259 reported that, in a model of peanut allergy in BALB/c mice, allergeninduced diarrhea and other features of the response were also partially diminished in mice deficient for the FceRIa chain. Adoptive transfer of WT BMCMCs, but not FceRIa À / À or Il-13 À / À BMCMCs, restored diarrhea in FceRIa-deficient mice, suggesting that this feature is dependent on IgE-mediated activation of MCs and on the release of IL-13 by MCs.
Little is known about the mechanism(s) leading to sensitization with food allergens. Forbes et al. 260 showed that transgenic mice that overexpress IL-9 have increased numbers of intestinal MMCs, associated with an increased intestinal permeability, which can enhance oral sensitization to OVA administered without an adjuvant. Epidemiologic studies have demonstrated that cutaneous inflammation associated with atopic dermatitis is a significant risk factor for the development of food allergies. [261] [262] [263] Recently, Noti et al. 263 reported that epicutaneous sensitization of mice to food antigens (OVA or peanut extract) applied to an atopic dermatitis-like skin lesion (which leads to increased levels of TSLP in the skin) followed by an oral challenge with the antigen promoted intestinal Th2-driven inflammation and increased numbers of intestinal MMCs. Such features are much diminished in mice deficient for the TLSP receptor or IgE, or in mice in which basophils have been depleted (but the authors did not assess responses of MC-deficient mice in this model). These results indicate that a ''TSLP-basophil axis'' can contribute to the development of IgE-mediated intestinal MMCs expansion and food allergy in mice sensitized epicutaneously with food allergens. 263 Burton et al. 264 recently developed an adjuvant-free model of peanut allergy using mice with a disinhibiting mutation in the IL-4 receptor a chain (il4raF709 mice), which results in amplified signaling on interaction of the receptor with the Th2 cytokines IL-4 or IL-13 but not constitutive activation. Oral sensitization of il4raF709 mice with peanut, followed by oral challenge with peanut, led to the expansion and activation of intestinal MMCs, and the development of diarrhea, intestinal inflammation, and hypothermia. The authors used MCdeficient Mcpt5-Cre; DTA mice and IgE-deficient mice to demonstrate that, in this model, both MCs and IgE were required for induction of antibody and Th2-cell-mediated responses to peanut ingestion, as well as for the suppression of expansion of regulatory T (Treg) cells. MC-targeted genetic deletion of the FceRI signaling kinase Syk in Mcpt5-Cre;Syk fl/fl mice also prevented peanut sensitization. Therefore, in addition to their key effector role during many allergic reactions, under certain circumstances, MCs and IgE also appear to be able to amplify sensitization to certain food allergens such as peanut, as well as participate in the suppression of tolerance.
ROLES OF MAST CELLS IN DEFENSE AGAINST MUCOSAL PATHOGENS
MCs are located at sites exposed to invading pathogens, such as the skin, the gut, the lung, and the genitourinary mucosa. MCs are, therefore, likely to be among the first innate cells (together with macrophages and dendritic cells) to respond to such pathogens. Studies in mice indicate that MCs can contribute to multiple defense strategies against various pathogens, including parasites (Figure 2) , bacteria, and viruses, 79, [265] [266] [267] [268] but that, in certain settings, MCs can contribute to the pathology associated with such infections.
Parasite infections
Parasite infections that involve the intestines and provoke the development of Th2 responses are often associated with a large expansion in MMCs in rodents, [269] [270] [271] and with an expansion of MMC populations in monkeys 272 and humans. 273 Space does not permit a comprehensive discussion of the complex innate and adaptive immune mechanisms that are thought to contribute to helminth clearance. [274] [275] [276] [277] Instead, we will review briefly some of the evidence indicating that MCs can influence aspects of these responses. Woodbury et al. 269 demonstrated that, in rats infected with T. spiralis or Nippostrongylus brasiliensis, systemic secretion of the rat MC-associated chymase rMCP-2 coincides with the immune expulsion of these nematodes. and Trichinella muris. 285, 286 Most of these studies show that such c-kit mutant MC-deficient mice have a delay in intestinal worm clearance during the primary infection. However, due to the inability to engraft intestinal MMCs in such c-kit mutant mice by the systemic adoptive transfer of MCs, 155, 177, 287, 288 it is not possible to know to what extent the delays in parasite clearance detected in these MC-deficient mice reflect their lack of MMCs vs. one or more of their other phenotypic abnormalities (including their deficiency on intestinal cells of Cajal, which results in abnormal gut motility 164 ). However, other lines of evidence support an important contribution for MCs in intestinal worm clearance. Ha et al. 283 showed that engraftment with total BM cells accelerated expulsion of T. spiralis in Kit W/W-v mice. Expulsion of T. spiralis was significantly delayed in mice lacking the chymase MCPT1, which suggests an important contribution of intestinal MMCs and MCPT1 in the clearance of this infection. 271 Although the kinetics of T. spiralis expulsion from the small intestine were similar between MCPT6-deficient and WT mice, the MCPT6-deficient mice had diminished levels of eosinophils in infected skeletal muscle. 289 Recently, Blankenhaus et al. 290 showed that c-kit-independent MC-deficient BALB/c-Cpa3
Cre/ þ mice (which, beside their MC deficiency, also have reduced basophil numbers 172 ) exhibited increased parasite burden in the small intestine following infection with S. ratti.
Although the results described above suggest potentially important roles for MMCs and some of their associated chymases in worm expulsion, it is possible that in some parasite infections the effects of MCs might actually favor the parasite. For example, anti-SCF treatment diminished intestinal MMC hyperplasia in rats infected with N. brasiliensis or T. spiralis, but such anti-SCF treatment decreased parasite egg production during N. brasiliensis infection. 291 Similarly, during a primary infection with N. brasiliensis, c-kit mutant MC-deficient Ws/Ws rats exhibited reduced numbers of eggs in the feces at day 8 of infection versus the correponding WT rats. 292 Neither study proved that MCs were responsible for the observed effects, but the results are intriguing in suggesting that some parasites may have learned how to exploit MC-associated effector mechanisms to their own advantage.
IL-3 can promote the expansion of intestinal MMCs in mice 51, 283 and treatment with IL-3 accelerates expulsion of S. ratti. 283 Both Kit W/W-v mice and mice lacking IL-3 exhibited a delay in S. venezuelensis expulsion, and this delay was greatly enhanced when these deficiencies were combined (i.e., in Il-3 À / À ; Kit W/W-v mice, in which infection provoked little or no expansion of basophil or MMC populations). 51 These findings indicate that one of the functions of IL-3 in this setting is to expand populations of hematopoietic effector cells, and are consistent with the possibility that both MCs and basophils contribute to expulsion of S. venezuelensis during the primary infection.
IL-9 also has an important role in the expansion of intestinal MMCs during parasite infection and transgenic mice that overexpress IL-9 have increased intestinal MMCs and increased efficiency of worm expulsion during infection with T. spilaris. 181 There is evidence that IL-9-mediated MC activation is also a key mechanism mediating S. ratti expulsion in mice. 290 This mechanism cannot be generalized to all parasites, as in the case of infection with N. brasiliensis, it appears that neither IL-9 nor MCPT1 influences worm expulsion. 271, 293 Most studies of the roles of MCs in parasite infection have focused on the primary responses to the infection (Figure 2) . Many parasites induce strong antibody responses, including high levels of antigen nonspecific IgE as well as antigen-specific IgE and IgG antibodies, and secondary infections are often associated with a more rapid expulsion of the parasites than occurs in the primary infection. [294] [295] [296] However, it is not yet clear to what extent the interactions of such antibodies with MCs importantly contribute to such secondary responses. Although there have been few studies of secondary parasite infections in genetically MC-deficient mice, numbers of MMCs and serum MCPT1 levels were significantly higher in BALB/c WT mice at day 3 after secondary vs. primary infections with T. spiralis, and worm burden at that time was significantly less in the secondary than in the primary infection. 181 Given that the co-engagement of FcgRIIB with FceRI can diminish antigen-dependent MC activation, 297, 298 it will be important to investigate whether this or other mechanisms can downregulate or otherwise alter MC responses during secondary parasite infections, as well as to determine whether MCs can confer benefits to the host or the parasite in such settings.
Bacterial infections
Several studies have indicated that MCs can have an important role in enhancing survival during models of experimental bacterial sepsis in mice. Many of these data were obtained using the cecal ligation and puncture (CLP) model in which commensal bacteria are allowed to escape from the cecum into the peritoneum, and most of the studies employing MC-deficient mice 80 and that MC-derived IL-12, 306 as well as MC expression of the cysteinyl protease dipeptidyl peptidase I 302 and the transcription factor Smad3, 307 are also required for optimal survival during the CLP model.
MCs also can be activated by the endogenous peptide endothelin-1 (ET-1), primarily through the ET(A) receptor. Activation by ET-1 promotes MC degranulation and the release of proteases, which in turn can degrade ET-1. MC proteasedependent degradation of ET-1 can contribute to optimal survival during CLP, which is associated with markedly elevated levels of ET-1, 301 and CPA3 is the critical protease that mediates degradation of ET-1. 81, 83 Other MC-associated proteases also have been implicated in defense against bacteria.
Studies in Mcpt4
À / À mice indicate that the chymase MCPT4 has effects that can enhance survival in a moderately severe model of CLP, perhaps, in part, through the degradation of TNF. 305 Orinska et al. 308 reported evidence that intracellular IL-15 expression in MCs can transcriptionally limit the amount of the chymase MCPT2 in the cells, resulting in decreased MC antibacterial properties and reduced survival of the mice after CLP.
MCs can mediate neutrophil recruitment after intraperitoneal (i.p.) injection of Klebsiella pneumoniae, probably via multiple mechanisms including the release of TNF, 304 and the tryptase MCPT6. 309, 310 There is evidence that MCs can enhance resistance to pulmonary infection with Mycoplasma pneumonia. 311 Histamine has an important role in this model, but neutrophils, rather than MCs, were the major source of histamine in the lungs of the infected mice. 115 MCs also can contribute to Clostridium difficile toxin A-induced intestinal fluid secretion and neutrophil infiltration. 312 Malaviya et al.
313
reported that, during infection with E. coli, neutrophil recruitment and bacterial clearance is controlled by JAK3 activation in MCs; this effect was attributed to the diminished ability of Jak3 À / À MCs to produce TNF. By contrast, there is evidence from work in MC knock-in mice that MC-derived TNF can enhance bacterial growth and hasten death after i.p. inoculation of Salmonella typhimurium.
158
Urinary tract infections, mainly caused by uropathogenic E. coli, represent one of the most common bacterial infections in humans. 314 Using the MC knock-in approach in c-kit mutant mice, Shelburne et al. 315 demonstrated that MCs and MCderived TNF can amplify the protective adaptive immune response to infection with uropathogenic E. coli by promoting: (1) recruitment of dendritic cells at the site of infection (in this case the footpad), (2) migration of dendritic cells into the draining lymph nodes, and (3) production of E. coli-specific IgG and IgM antibodies. Increased numbers of surviving bacteria were found in the urinary bladder of c-kit mutant MCdeficient Kit W/W-v mice as compared with Kit þ / þ mice following experimental infection with E. coli. 316 Chan et al. 317 compared the kinetics of E. coli clearance in the bladder and kidneys of infected mice and found that, although all bacteria were cleared within 5 days in the kidneys, significant numbers of bacteria were still found in the bladder as late as 1 month after infection. They demonstrated that this prolonged bacterial survival was due to production of IL-10, and the absence of significant levels of E. coli-specific antibodies, in the bladder. 317 There is evidence that mouse MCs can represent an important source of IL-10 during inflammation 141, 317 and that MC-derived IL-10 can: (1) limit inflammation during contact hypersensitivity 141 (although these findings have been recently challenged by Dudeck et al.
168
) as well as (2) diminish the severity of experimental graft-versus-host disease. 318 In line with these findings, Chan et al. 317 demonstrated that MC-derived IL-10 contributed importantly to the suppression of E. coli-specific antibody production during experimental urinary tract infection in mice and accounted, at least in part, for the persistence of E. coli in the bladder. Therefore, MCs may have a dual role during E. coli infections in the bladder, first reducing numbers of bacteria by promoting aspects of the initial response to infection but later limiting the antibody response to E. coli by producing IL-10.
317
Because c-kit mutant MC-deficient mice have many c-kitrelated phenotypic abnormalities that may influence the responses of such animals to infection (including those which do or do not affect MC numbers or functions), 152, 158, 175 it will be of great interest to continue to evaluate the roles of MCs in infection models using some of the newer, c-kit-independent, models of MC deficiency. For example, Rönnberg et al. 319 recently reported that peritoneal MCs are activated by Staphylococcus aureus in vitro; however, the authors used c-kit-independent MC-deficient Mcpt5-Cre; DTA þ mice to demonstrate that MCs do not influence the in vivo manifestations of one model of i.p. S. aureus infection. Such work will help to clarify which roles of MCs are variably redundant with those of other cell types (including neutrophils or macrophages, among others) and which MC roles-whether to enhance and/or suppress aspects of these innate or acquired immune responses-may be nonredundant.
Viral infections
MCs have been implicated in the defense against certain viruses, although there have been relatively few studies in this area. 79 Sendai virus can induce histamine release from rat peritoneal MCs ex vivo 320 and infection of rats with Sendai virus results in increased numbers of MCs in the lung. 321 63, 326 ) significantly increased the histopathological severity of the myocardial lesions induced by the virus (albeit not to levels observed in WT mice). 325 By contrast, studies in Kit W-sh/W-sh mice, including engraftment of these mice with BMCMCs, showed that MCs can participate in host defense against vaccinia virus, and MC production of the antimicrobial peptide cathelicidin was implicated as a key defense mechanism against this virus. 327, 328 In humans, infection with dengue virus leads to increased levels of MC chymase in the serum, 329 and chymase levels are significantly higher in patients with severe dengue fever (also known as dengue hemorrhagic fever) as compared with patients with dengue fever. 329, 330 323 MCs and their progenitors might also serve as a reservoir for latent virus, a role which would be detrimental to the host. [333] [334] [335] [336] In line with the potential of MCs to help in orchestrating protective adaptive responses at mucosal sites, McLachlan et al. 337 demonstrated that certain small molecules (''MC activators'') are potent mucosal adjuvants, and provided evidence that these agents mediate such functions in a largely MC-dependent manner. The so-called ''MC activators'' comprise a family of structurally diverse cationic peptides and polymeric compounds that can induce strong MC degranulation;
338,339 such agents include compound 48/80 (c48/80), [340] [341] [342] and a variety of peptide toxins, such as MCdegranulating peptide, which is found in honeybee and bumblebee venoms. 343 Using the MC knock-in system in c-kit mutant mice, McLachlan et al. demonstrated that compound 48/80 (which promotes MC degranulation, but also has other effects) can act as a potent mucosal adjuvant when coadministered in the footpad with recombinant anthrax protective antigen, and that this adjuvant effect largely depends on MCs and MC-derived TNF. Importantly, vaccination with c48/80 coadministered with the vaccinia virus antigen B5R intranasally conferred protection against intranasal challenge with a normally lethal dose of vaccinia virus. 337 
CONCLUSIONS
We are in the midst of an interesting period in MC research. For many years, an increasing understanding of the diversity of MC products, signaling mechanisms, and interactions with other cell types has led to the generation of many attractive hypotheses about the diverse potential effector and immunoregulatory roles of MCs in the biology and pathology of mucosal tissues (and in other settings). Increasingly, these hypotheses are being tested in ways that permit us to accrue definitive evidence regarding the nature, and the importance, of such proposed MC roles. In addition to long-established mouse model systems, including ''MC knock-in c-kit mutant mice'' and various MC protease-deficient mice, there are now many promising new models of constitutive or inducible MC deficiency, as well as many new models for achieving the targeted deletion of individual products in MCs. On the basis of the results obtained so far with both the older and newer models for MC research, we think that the most robust conclusions about the nature and importance of the roles of MCs in various biological responses in vivo, in mucosal tissues and other sites, probably will be derived from studies employing multiple informative model systems. 152 Taken together, such approaches offer many opportunities to obtain increasingly solid evidence to support (or discard) notions about how MCs might influence the development, physiology, homeostasis, immunology, and pathology of mucosal tissues. It hardly needs mentioning that findings in mice do not prove that the same processes occur in humans, and there are likely to be multiple differences in the details of immune responses and disease pathogenesis in the two species, not just differences in the roles of MCs in such settings. However, preclinical studies using models in which individual cells or products can be manipulated offer the promise of revealing pathways that, with luck, might be exploited to provide benefit to those suffering from any of the diverse mucosal pathologies in which MCs have been implicated. Time will tell to what extent this hope will be realized. 
